Patents by Inventor Vuong Trieu

Vuong Trieu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods of delivery of pharmacological agents
    Patent number: 9012519
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: April 21, 2015
    Assignee: Abraxis Bioscience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
  • Compositions and methods of delivery of pharmacological agents
    Patent number: 9012518
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: April 21, 2015
    Assignee: Abraxis BioScience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
  • Nanoparticle Formulations in Biomarker Detection
    Publication number: 20150104520
    Abstract: The present invention relates to compositions and methods of treatment of cancer patients with cytotoxic drugs in particular the use of cytotoxic drugs encapsulated in a diblock copolymer formulation where the composition is stable in protein free media and less stable in protein containing media such as serum, in particular the treatment of ovarian.
    Type: Application
    Filed: April 7, 2014
    Publication date: April 16, 2015
    Inventors: Vuong Trieu, Larn Hwang
  • NANOPARTICLE COMPRISING RAPAMYCIN AND ALBUMIN AS ANTICANCER AGENT
    Publication number: 20150050356
    Abstract: The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.
    Type: Application
    Filed: October 28, 2014
    Publication date: February 19, 2015
    Inventors: Neil P. DESAI, Patrick SOON-SHIONG, Vuong TRIEU
  • SPARC and methods of use thereof
    Patent number: 8946169
    Abstract: The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: February 3, 2015
    Assignee: NantBioScience, Inc.
    Inventors: Vuong Trieu, Neil P. Desai, Patrick Soon-Shiong
  • SPARC and methods of use thereof
    Patent number: 8916204
    Abstract: The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: December 23, 2014
    Assignee: Abraxis BioSciences, LLC
    Inventors: Vuong Trieu, Neil P. Desai, Patrick Soon-Shiong
  • SPARC BINDING SCFVS
    Publication number: 20140370016
    Abstract: The invention provides compositions comprising SPARC binding ScFc and its use.
    Type: Application
    Filed: July 31, 2014
    Publication date: December 18, 2014
    Applicant: ABRAXIS BIOSCIENCE, LLC
    Inventor: Vuong Trieu
  • Nanoparticle comprising rapamycin and albumin as anticancer agent
    Patent number: 8911786
    Abstract: The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.
    Type: Grant
    Filed: March 7, 2008
    Date of Patent: December 16, 2014
    Assignee: Abraxis Bioscience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
  • SPARC BINDING SCFVS
    Publication number: 20140341905
    Abstract: The invention provides compositions comprising SPARC binding ScFc and its use.
    Type: Application
    Filed: August 5, 2014
    Publication date: November 20, 2014
    Applicant: ABRAXIS BIOSCIENCE, LLC
    Inventor: Vuong Trieu
  • SPARC BINDING SCFVS
    Publication number: 20140341904
    Abstract: The invention provides compositions comprising SPARC binding ScFc and its use.
    Type: Application
    Filed: August 4, 2014
    Publication date: November 20, 2014
    Applicant: ABRAXIS BIOSCIENCE, LLC
    Inventor: Vuong Trieu
  • NANOPARTICLE THERAPEUTIC AGENTS, THEIR FORMULATIONS, AND METHODS OF THEIR USE
    Publication number: 20140314672
    Abstract: Nanoparticle therapeutic agents, formulations that include the nanoparticle therapeutic agents, and methods for treating diseases treatable by the therapeutic agents.
    Type: Application
    Filed: April 3, 2014
    Publication date: October 23, 2014
    Applicant: IGDRASOL, INC.
    Inventor: Vuong Trieu
  • NANOPARTICLE FORMULATIONS AND USES THEROF
    Publication number: 20140302157
    Abstract: The present invention provides compositions comprising nanoparticles comprising: 1) a drug, such as a hydrophobic drug derivative; and 2) a carrier protein. Also provided are methods of treating diseases (such as cancer) using the compositions, as well as kits and unit dosages.
    Type: Application
    Filed: February 28, 2014
    Publication date: October 9, 2014
    Applicant: Abraxis BioScience, LLC
    Inventors: Neil P. DESAI, Chunlin TAO, Tapas DE, Sherry Xiaopei CI, Vuong TRIEU
  • Compositions and methods of delivery of pharmacological agents
    Patent number: 8846771
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: September 30, 2014
    Assignee: Abraxis BioScience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
  • SPARC binding peptides and uses thereof
    Patent number: 8821836
    Abstract: The invention provides SPARC and Albumin binding peptides for the targeting of disease sites, such as tumors, with therapeutic and diagnostic agents. In particular, compositions comprising SPARC binding peptide-Antibody Fc domain fusion proteins and methods of their use are disclosed.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: September 2, 2014
    Assignee: Abraxis BioScience, LLC
    Inventor: Vuong Trieu
  • SPARC binding ScFvs
    Patent number: 8809507
    Abstract: The invention provides compositions comprising SPARC binding ScFc and its use.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: August 19, 2014
    Inventor: Vuong Trieu
  • SPARC ANGIOGENIC DOMAIN AND METHODS OF USE
    Publication number: 20140094416
    Abstract: The invention provides compositions and methods which exploit the discovery of the SPARC carboxy angiogenic domain.
    Type: Application
    Filed: November 12, 2013
    Publication date: April 3, 2014
    Applicant: Abraxis BioScience, LLC
    Inventors: Vuong Trieu, Daniel Knauer, Neil Desai
  • NANOPARTICLE FORMULATIONS AND USES THEREOF
    Publication number: 20140080901
    Abstract: The present invention provides compositions comprising nanoparticles comprising: 1) a drug, such as a hydrophobic drug derivative; and 2) a carrier protein. Also provided are methods of treating diseases (such as cancer) using the compositions, as well as kits and unit dosages.
    Type: Application
    Filed: February 28, 2013
    Publication date: March 20, 2014
    Applicant: ABRAXIS BIOSCIENCE, LLC
    Inventors: Neil P. DESAI, Chunlin TAO, Tapas DE, Sherry X. CI, Vuong TRIEU
  • SPARC ANGIOGENIC DOMAIN AND METHODS OF USE
    Publication number: 20130323263
    Abstract: The invention provides compositions and methods which exploit the discovery of the SPARC carboxy angiogenic domain.
    Type: Application
    Filed: March 11, 2011
    Publication date: December 5, 2013
    Applicant: ABRAXIS BIOSCIENCE, LLC
    Inventors: Vuong Trieu, Neil Desai
  • NANOPARTICLE COMPRISING RAPAMYCIN AND ALBUMIN AS ANTICANCER AGENT
    Publication number: 20130280336
    Abstract: The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.
    Type: Application
    Filed: February 27, 2013
    Publication date: October 24, 2013
    Inventors: Neil P. DESAI, Patrick SOON-SHIONG, Vuong TRIEU
  • SPARC MICROENVIRONMENT SIGNATURE, PLASMA SPARC, AND LDH AS PROGNOSTIC BIOMARKERS IN THE TREATMENT OF CANCER
    Publication number: 20130281376
    Abstract: The invention provides multiparametric anti-SPARC antibody-based techniques for treating cancers as well as determining prognosis and predicting the response to therapy, including chemotherapy, radiotherapy, surgical therapy and combination therapies.
    Type: Application
    Filed: October 7, 2011
    Publication date: October 24, 2013
    Applicant: ABRAXIS BIOSCIENCE, LLC
    Inventors: Vuong Trieu, Larn Hwang, Kouros Motamed, Xiping Liu, Neil Desai